Navigation Links
Janssen Launches EXPLORER, Global Cardiovascular Research Program, Beginning with Five New Studies in Patients with Unmet Medical Needs
Date:3/8/2013

>® 1 time a day with your evening meal.
If you miss a dose of XARELTO®, take it as soon as you remember on the same day.  Take your next dose at your regularly scheduled time. 
  • Blood clots in the veins of your legs or lungs:
    • Take XARELTO® once or twice a day as prescribed by your doctor.
    • Take XARELTO® with food at the same time each day.
    • If you miss a dose of XARELTO®:
      • and take XARELTO 2 times a day: Take XARELTO® as soon as you remember on the same day.  You may take 2 doses at the same time to make up for the missed dose.  Take your next dose at your regularly scheduled time.
      • and take XARELTO® 1 time a day: Take XARELTO® as soon as you remember on the same day.  Take your next dose at your regularly scheduled time.
  • Hip or knee replacement surgery: Take XARELTO® 1 time a day with or without food.  If you miss a dose of XARELTO®, take it as soon as you remember on the same day.  Take your next dose at your regularly scheduled time.

    • If you have difficulty swallowing the tablet whole, talk to your doctor about other ways to take XARELTO.
    • Your doctor will decide how long you should take XARELTO®. Do not stop taking XARELTO® without talking to your doctor first.
    • Your doctor may stop XARELTO® for a short time before any surgery, medical or dental procedure. Your doctor will tell you when to start taking XARELTO® again after your surgery or procedure.
    • Do not run out of XARELTO®. Refill your prescription for XARELTO®<
      '/>"/>

    SOURCE Janssen
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11

    Related medicine technology :

    1. Janssen Research & Development Submits XARELTO® (rivaroxaban) to U.S. FDA for the Treatment and Prevention of Recurrent Venous Thromboembolism
    2. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin to Treat Patients with Type 2 Diabetes
    3. Janssen Announces Initiation Of Phase 3 Development Program For Sirukumab In Rheumatoid Arthritis
    4. Janssen Biotech Announces Global License and Development Agreement for Investigational Anti-Cancer Agent Daratumumab
    5. West Announces Agreement with Janssen Biotech to Develop and Commercialize a New Self-injection Technology
    6. Janssen Announces Collaboration with Vertex on Phase 2 Study to Investigate an All-Oral Regimen of Simeprevir (TMC435) and VX-135 for Treatment of Hepatitis C
    7. Janssen and Johnson & Johnson to Provide Webcast Presentation of Immunology Pivotal Phase 3 Data Being Presented at the American College of Rheumatology Annual Meeting
    8. Efficacy and Safety Data from Phase 2B Trials of Janssens Simeprevir in Hepatitis C Patients with Advanced Fibrosis of the Liver Presented at Annual Meeting of the American Association for the Study of Liver Diseases
    9. Janssen Research & Development Announces Establishment of Global Cross-Pharmaceutical Clinical Trial Investigator Databank
    10. Janssen Research & Development Submits New Drug Application to U.S. FDA for Canagliflozin/Metformin Fixed-Dose Combination Therapy to Treat Patients with Type 2 Diabetes
    11. Janssen Labs at San Diego Expands to Add Concept Lab and Open Collaboration Space to Accommodate Individual Entrepreneurs and Additional Life Science Start-Ups
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... , Jan. 15, 2014  Manufacturers, suppliers and distributors ... able to protect their most important business assets, ... ) Because of the highly-competitive ... remains one of the most litigious industry sectors ...
    (Date:1/15/2014)... Inc. (Nasdaq: ECTE ) ("Echo"), a medical ... non-invasive, wireless continuous glucose monitoring system, today announced that ... CEO of Echo Therapeutics, will present at "TEN", Noble ... Mr. Doman will make a corporate presentation to ...
    (Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: PharmaPoint: Atopic ... Analysis to 2022 http://www.reportlinker.com/p01957657/PharmaPoint-Atopic-Dermatitis---India-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology ... India Drug Forecast and Market Analysis to ...
    Breaking Medicine Technology:Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
    (Date:7/9/2014)... If you think winning is one of the key ... Winning along with other mental bonuses ranked near the bottom ... one of 11 big fun factors, according to a new ... when it comes to the "fun" factor, very little research ... into this elusive conceptuntil now. , The results of this ...
    (Date:7/9/2014)... Medicine at the University of Pennsylvania in collaboration with ... million grant from the National Cancer Institute (NCI) to ... patients with malignant pleural mesothelioma, a rare, aggressive and ... lining of the lungs and is caused almost exclusively ... clinical trial and additional studies looking at the effects ...
    (Date:7/9/2014)... stromal support cells and immune cells and the ... the development of diseases could open new therapeutic ... the conclusion of a review article by scientists from ... Nature . , Prof. Peter Carmeliet: "Consider the review ... cancer cells has been examined in minute detail for ...
    (Date:7/9/2014)... N.Y. Although feelings are personal and subjective, ... code that objectively represents emotions across different senses, ... by Cornell University neuroscientist Adam Anderson. , "We ... the orbitofrontal cortex, an area of the brain ... code which captures an individual,s subjective feeling," says ...
    (Date:7/9/2014)... than watching World Cup highlights, Brian Williams refreshing old ... unfortunate positions on railings. A University of Colorado Cancer ... shows that YouTube also allows researchers, journals, and ... topics of skin cancer and prevention. , "No matter ... of how we communicate around the world," says Chante ...
    Breaking Medicine News(10 mins):Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 2Health News:Being a good sport ranks as the top 'fun' factor in study of youth sports 3Health News:Penn mesothelioma program receives $8 million NCI grant 2Health News:Wake-up call for more research into cell metabolism 2Health News:Study cracks how the brain processes emotions 2Health News:Study of dermatology on YouTube shows new ways science reaches public 2
    ... dressing well given by an emergency doctor. There is no need ... cold. A brisk walk and exposure to sunlight will do you ... you want to avoid the ill-effects of cold weather. Just putting ... the answer. ,Dr Goerge Danke, professor of emergency medicine ...
    ... According to new study, a protein in the eye has ... researchers say this could lead to promising treatments for other// ... ,Scientists from the Schepens Eye Research Institute in Boston ... a therapeutic drug. The drug can then prevent the onset ...
    ... that breathing oxygen may cause some harm to cells. The ... people //with severe lung or heart disease.Oxygen supports the organs ... the blood. But oxygen is often given inappropriately. Overall the ... life'. ,A study by researchers at New York Medical ...
    ... at University of Illinois at Chicago could possibly help ... Dean of the College of Nursing at UIC, //and ... which is using warm booties as a way to ... The idea, says Shaver, is that better sleep occurs ...
    ... loss followed by weight gain is only a health risk ... are now well established to many. But weight, once lost,// ... that fluctuating weight may, in itself, predispose to heart disease ... a group of 5,428 middle-aged British men during a 12 ...
    ... observed that yoga therapy can reduce risk factors and improve ... aid improve physical, psychological and spiritual //health - or so ... England, reviewed the best evidence they could find on the ... - out of 11 - trials that were good enough ...
    Cached Medicine News:
    Lyphochek Assayed Chemistry Control requires no special diluent and has good reconstituted stability for enzymes and CO2. It is assayed for most major instruments and methodologies....
    Liquichek Therapeutic Drug Monitoring Control (TDM) is a liquid assayed control containing a comprehensive menu of therapeutic drugs, as well as many common ligands. Available in three levels....
    Lyphochek Urine Metals Control incorporates two levels of critical trace elements, heavy metals and organic metabolites, and is ideal for environmental and industrial testing....
    Liquichek Urine Chemistry Control is a liquid product ideal for monitoring urine chemistry testing procedures. It provides assayed values for urine tests commonly performed on chemistry analyzers and...
    Medicine Products: